VBI Vaccines (Nasdaq: VBIV) (“VBI”) is scheduled to present at the BIO CEO & Investor Conference on Tuesday, February 9th, 2016 at 1:00 PM ET. The event is being held at the Waldorf Astoria in New York, NY.

During the presentation, Jeff Baxter, VBI’s President and CEO, will provide an overview of VBI and its platform technologies, and will summarize recent developments in the company’s pipeline of vaccine candidates. Mr. Baxter will also discuss VBI’s planned merger with SciVac Therapeutics (TSX:VAC and OTCQX:SVACF) (“SciVac”). SciVac’s flagship product, Sci-B-Vac®, is a commercial hepatitis B vaccine approved for use in fifteen countries.“We expect 2016 to be a transformative year for VBI,” said Mr. Baxter. “We have been making excellent progress in advancing and expanding VBI’s pipeline of preventative and therapeutic vaccine candidates, and, by combining SciVac's assets and talent with our own, we intend to create a leading commercial-stage vaccine developer with a robust pipeline of vaccine candidates targeting large underserved markets.”

Now in its eighteenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. To schedule a one-on-one meeting with VBI management during the event, please contact ir@vbivaccines.com.

Event Details

  • Event: 18th Annual BIO CEO & Investor Conference
  • Date: Tuesday, February 9th, 2016
  • Time: 1:00 PM ET
  • Location: The Waldorf Astoria in New York, NY
  • Event Website: http://bit.ly/bioceo-2016